A Novel Method for Preparing Uniform Micro-Sized Dry Powder Formulations, Including Aggregation-Controlled VHH

Antibodies, Journal Year: 2025, Volume and Issue: 14(2), P. 29 - 29

Published: March 31, 2025

Background: The preparation of antibodies in powder form without changing their physicochemical properties may enable use new drug delivery system therapies or non-refrigerated storage. variable domain heavy-chain (VHHs) is more suited for this purpose than that conventional because VHHs’ high thermal stability and ability to refold. Methods: In report, the fine droplet drying (FDD) process was selected as powderization technique its favorable features, such mild conditions generation uniform particle sizes. aggregation, binding, particle, vitro inhalation prepared VHH powders (VHHps) were evaluated. Results: amount aggregated VHHs present VHHps depended on flow temperature during FDD process, with higher temperatures yielding a aggregation ratio. contrast, no significant difference binding activity observed between each VHHp native VHHs. However, degraded inactivated function, ultimately, only about 30% original functional, whereas remaining not showed little loss functionality, even after storage at room two years. Analysis samples revealed particles uniformly spherical single-micron size. property test. Conclusions: These findings suggest affords various formulations, including pharmaceutical formulations.

Language: Английский

---

Formulation and clinical translation of inhalable nanomedicines for the treatment and prevention of pulmonary infectious diseases

Drug Delivery and Translational Research, Journal Year: 2025, Volume and Issue: unknown

Published: April 29, 2025

Abstract Pulmonary infections caused by bacteria, viruses and fungi are a significant global health issue. Inhalation therapies gaining interest as an effective approach to directly target infected lung sites nanoparticle-based pulmonary delivery systems increasingly investigated for this purpose. In review, we provide overview of common infectious diseases review recent work on the application inhalable formulations diseases, formulation strategies, current research delivering nanomedicines. We also evaluate clinical development status, market landscape, discuss challenges that impede translation propose solutions overcome these obstacles, highlighting promising opportunities future advancements in field. Despite made products reaching market, notable gap persists translational research, with achieving product profile, availability appropriate vivo disease models, scale-up, related questions, likely hindering clinic. Graphical

Language: Английский

---

Unveiling the role of nanoparticle-based therapeutic strategies for pulmonary drug delivery

Journal of Drug Delivery Science and Technology, Journal Year: 2024, Volume and Issue: unknown, P. 106558 - 106558

Published: Dec. 1, 2024

Language: Английский

---

Nanoparticle-Mediated Delivery of Deferasirox: A Promising Strategy Against Invasive Aspergillosis

Bioengineering, Journal Year: 2024, Volume and Issue: 11(11), P. 1115 - 1115

Published: Nov. 5, 2024

Invasive aspergillosis (IA) is a deadly fungal lung infection. Antifungal resistance and treatment side effects are major concerns. Iron chelators vital for IA management, but systemic use can cause effects. We developed nanoparticles (NPs) to selectively deliver the iron chelator deferasirox (DFX) treatment.

Language: Английский

---